NewsAnti–IL-33 antibody stakes a first-in-class claim on moderate to severe atopic dermatitisAuthor:Michelle SullivanPublish date: February 22, 2018SAN DIEGO – Benefits lasted at least 2 months after one 300 mg IV infusion in a study of 12 patients.Read More
